Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Tuesday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Up 1.1 %

NYSE:BTX opened at $0.25 on Tuesday. Brooklyn ImmunoTherapeutics has a 52 week low of $0.17 and a 52 week high of $10.10. The stock’s fifty day moving average is $0.70 and its two-hundred day moving average is $1.32. The stock has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.11 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.